Document is current
Any future updates will be listed below
-
Authors
Doi, Kent https://orcid.org/0000-0002-0115-1439
Ikeda, Mahoko
Hayase, Naoki
Moriya, Kyoji
Morimura, Naoto
,
Maehara, Hiromu
Tagami, Shunsuke
Fukushima, Kazutaka
Misawa, Naho
Inoue, Yutaro
Nakamura, Hitomi
Takai, Daisuke
Kurimoto, Mio
Tokunaga, Kurato
Yamamoto, Miyuki
Hirayama, Ichiro
Horie, Ryohei
Endo, Yuri
Hiwatashi, Kengo
Shikama, Mio
Jubishi, Daisuke
Kanno, Yoshiaki
Okamoto, Koh
Harada, Sohei
Okugawa, Shu
Miyazono, Kohei
Seto, Yasuyuki
Inoue, Jun-ichiro
- License Information
-
More Information
Article History
Received: 3 June 2020
Accepted: 8 June 2020
First Online: 3 July 2020
Ethics approval and consent to participate
: This case series was approved by the institutional review board at the University of Tokyo (#3820). The institutional treatment board at The University of Tokyo Hospital approved the treatment protocol of antiviral agents of favipiravir and nafamostat mesylate (#2020001CL). Informed consent for treatment was obtained from each patient or legal representative.
: Not applicable
: One author (JI) has submitted a provisional application for a patent related to this work to USPTO under the application no. 62988962. The other authors declare that they have no conflicts of interest with the contents of this article.
